Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.

Journal article

Oral capecitabine (Xeloda) is an effective drug with favourable safety in adjuvant and metastatic colorectal cancer. Oxaliplatin-based therapy is becoming standard for Dukes' C colon cancer in patients suitable for combination therapy, but is not yet approved by the UK National Institute for Health and Clinical Excellence (NICE) in the adjuvant setting. Adjuvant capecitabine is at least as effective as 5-fluorouracil/leucovorin (5-FU/LV), with significant superiority in relapse-free survival ...

Expand abstract

Authors: Cassidy, J; Douillard, J; Twelves, C; McKendrick, J; Scheithauer, W

• Publication status: Published
• Journal: British journal of cancer
• Volume: 94
• Issue: 8
• Pages: 1122-1129
• Publication date: 2006-04-01
• DOI: 10.1038/sj.bjc.6603059
• EISSN: 1532-1827
• ISSN: 0007-0920
• Language: English
• Keywords: Health Resources; Great Britain; Disease-Free Survival; Chemotherapy, Adjuvant; Leucovorin; Quality of Life; Sensitivity and Specificity; Health Care Costs; Injections, Intravenous; Treatment Outcome; Time Factors; Remission Induction; Drug Costs; Fluorouracil; Cost-Benefit Analysis; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Deoxycytidine; Survival Rate; Neoplasm Staging; Drug Administration Schedule; Administration, Oral; Humans